Inactief instrument

Andere talen NeoStem Inc Nasdaq

Aandelen

US6406504042

slotkoers Nasdaq Andere beurzen
- ^USD	-

09/05	Transcript : Lisata Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	Lisata Therapeutics, Inc. Rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Lisata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events	08/05
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events	08/05
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024	02/05
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024	02/05
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	24/04
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors	23/04
Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer	23/04
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23/04
Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23/04
Lisata Therapeutics, Inc. Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer	17/04
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09/04
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09/04
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events	03/04
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	21/03
Sector Update: Health Care Stocks Higher in Afternoon Trading	21/03
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug	21/03
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma	21/03
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ	04/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen NeoStem Inc Nasdaq

Aandelen

US6406504042

Andere talen

Filters